MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in two Phase I/II clinical trials, in combination with Vidaza(R) for hematological malignances and with Gemzar(R) in solid tumors; and in four Phase II monotherapy clinical trials in hematological malignancies.
About Hodgkin's Lymphoma
Hodgkin's lymphoma (HL) is a cancer of the lymphatic system that begins in the lymph nodes and progresses to other organs, including the lungs, liver, bone and bone marrow. It is characterized by the presence of Reed-Sternberg cells. Currently, there is no known cause of the disease, but epigenetic alterations including histone acetylation, have been identified. In addition, the Epstein-Barr virus, HIV and familial history are known risk factors. The disease is slightly more prevalent in men than women, and the median age of diagnosis is 38.
MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical
company focused on the discovery, development and commercialization of
novel therapeutics for cancer. The Company's lead product, MGCD0103, is an
oral isotype-selective HDAC inhibitor presently in multiple clinical trials
for solid tumors and hematological malignancies, including Phase II
monotherapy and Phase I/II combination trials with Vidaza(R) and Gemzar(R).
MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and
VEGF receptor tyrosine kinases. In addition, MethylGene has several
preclinical programs: MGCD290 an HDAC inhibitor in combination with azoles
for fungal infections; an HDAC program for Huntington's disease; a sirtuins
program for cancer; and a beta-lactamase program to overcome antibiotic
|SOURCE Pharmion Corporation|
Copyright©2007 PR Newswire.
All rights reserved